Fulcrum Therapeutics (FULC)

• Market cap: $651M
• 1 day: -1.2%
• 5 days: -12.73%
• 1 month: -24.02%
• 3 months: 6.82%
• 6 months: 40.6%
• Year to date: -9.62%
• 1 year: 101.84%
• 5 years: -14.55%
• 10 years: -26.89%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45